News Dr. Lal PathLabs Limited Bombay S.E.

Equities

LALPATHLAB

INE600L01024

Market Closed - Bombay S.E. Other stock markets 06:00:53 2024-07-16 EDT			5-day change	1st Jan Change
2,996 ^INR	-0.09%		+3.07%	+16.39%

06-29	Dr. Lal PathLabs Limited Declares Final Dividend for the Financial Year Ended March 31, 2024	CI
05-14	Nomura Upgrades Dr. Lal Pathlabs to Buy From Neutral, Adjusts Price Target to INR2,713 From INR2,505	MT

Summary

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Dr. Lal PathLabs Limited Declares Final Dividend for the Financial Year Ended March 31, 2024	06-29	CI
Nomura Upgrades Dr. Lal Pathlabs to Buy From Neutral, Adjusts Price Target to INR2,713 From INR2,505	05-14	MT
Dr. Lal Pathlabs' Fiscal Q4 Consolidated Net Profit Rises; Share Up 6%	05-13	MT
Transcript : Dr. Lal PathLabs Limited, Q4 2024 Earnings Call, May 10, 2024	05-10
India's Dr. LalPath Labs posts higher Q4 profit rises on healthy testing demand	05-10	RE
Dr. Lal PathLabs Limited Recommends Final Dividend for the Financial Year Ended March 31, 2024	05-10	CI
Dr. Lal PathLabs Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024	05-10	CI
Dr. Lal Pathlabs Limited Announces Resignation of Bharath U as Chief Executive Officer, Effective May 9, 2024	04-26	CI
Dr Lal Pathlabs Names CEO	03-17	MT
Dr. Lal PathLabs Limited Appoints Shankha Banerjee as Chief Executive Officer, Effective May 21, 2024	03-16	CI
Dr. Lal Pathlabs Limited Announces Resignation of Bharath U as Chief Executive Officer	03-03	CI
Nomura Adjusts Dr. Lal Pathlabs’ Price Target to INR2,505 From INR2,465, Keeps at Neutral	02-05	MT
Dr. Lal Pathlabs' Consolidated Profit Jumps in Fiscal Q3; EPS, Revenue Miss Estimates	02-01	MT
Dr. Lal PathLabs Seeks M&A	02-01	CI
Transcript : Dr. Lal PathLabs Limited, Q3 2024 Earnings Call, Feb 01, 2024	02-01
India's Dr. Lal PathLabs posts 54% jump in Q3 profit on flu, COVID tests	02-01	RE
Dr. Lal PathLabs Limited Approves Second Interim Dividend for the Fiscal Year 2023-24	02-01	CI
Dr. Lal PathLabs Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	02-01	CI
Dr. Lal Pathlabs Board to Consider Second Interim Dividend for Fiscal 2024	01-25	MT
Nomura Upgrades Dr. Lal Pathlabs to Neutral From Reduce, Adjusts Price Target to INR2,465 From INR,2002	11-06	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Dr. Lal PathLabs Limited Bombay S.E.

Equities

LALPATHLAB

INE600L01024

Summary

Filters